Rheumatoid arthritis is a chronic debilitating disease. Nowadays, rheumatologists aim at early remission of the disease. Despite the efficacy of many available disease-modifying anti-rheumatic drugs (DMARDs) and different biologics, not all patients respond to these agents. Therefore, new drugs are in needs. Tocilizumab, an interleukin-6 receptor inhibitor, has shown to be effective for the management of rheumatoid arthritis and has been approved for use in Europe and Japan.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that can result in joint deformity, disability and increased mortality. With the emergence of biologic therapies, the treatment of rheumatoid arthritis has revolutionized. Nowadays, the management goal is early remission of the disease. With the presence of different treatment modalities, however, not all patients respond. And even among responders, some of them only show partial improvement.
Other therapeutic options are actively under search. Interleukin-6 (IL-6) is one of the targets.
It is a pleotropic proinflammatory cytokine involved in multiple immunologic processes. It is found to be overexpressed in synovial tissue in RA patients and its levels correlate with disease activity as well as joint damage. Tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, can inhibit the IL-6 mediated proinflammatory activities. Studies have shown its efficacy in controlling RA. In Europe and Japan, tocilizumab has been approved for treating RA.
Tocilizumab
Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody of the IgG1 subclass. It binds to both soluble and membrane-expressed IL-6 receptors selectively and competitively. Through the inhibition of the glycoprotein 130 pathway, proinflammatory activities as mediated by IL-6 are blocked. There are a number of phase III trials conducted for evaluating its efficacy and safety profile in the management of RA. Results are encouraging and offer hope to patients with RA.
Clinical Efficacy

ACR Responses and DAS Remission
Eight phase III trials studying on the use of tocilizumab in RA were reviewed. In general, adult patients ≥18 years old with active disease for at least 6 months were recruited. RA were defined according to the American College of Rheumatology criteria while active disease referred to those with 6 or more swollen joints, 8 or more tender joints and erythrocyte sedimentation rate (ESR) of at least 28 mm/hr or C-reactive protein of at least 1 mg/dL. Common exclusion criteria included significant concomitant diseases and active infection. [1] [2] [3] [4] [5] Patients with deranged liver function, malignancies, immunodeficiency, severe anaemia, leucopenia, neutropenia, thrombocytopenia, tuberculosis, hepatitis B or C were also excluded in some of the trials. [1] [2] [3] Table 1 summarises the average disease duration and average disease activity in terms of DAS28. In these trials, tocilizumab was used either as monotherapy or as combination therapy with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs). Different groups of RA patients were targeted.
These included inadequate responders to DMARDs and anti-TNF therapy and patients who were methrotrexate-naïve.
The effect of tocilizumab was studied in patient who had inadequate response to methotrexate (MTX) in the OPTION 1 trial. 59%, 44% and 22% of patient who received tocilizumab 8 mg/kg every 4 weeks in combination with MTX achieved ACR20, ACR50 and ACR70 response respectively at week 24. While ACR20, ACR50 and ACR70 response rates were 26%, 11% and 2% in the control group. DAS28 remission at 24 weeks was also significantly more in the tocilizumab group (27%) as compared to the control arm (0.8%). In the TOWARD 6 trial, patients who have failed DMARDs were studied. Among more than 1200 patients recruited, 76% were treated with one DMARD while 23% were treated with more than 1 DMARDs. MTX was the most commonly used DMARD. At week 24, the proportion of ACR20 responders were higher in the group who received tocilizumab and DMARDs (included MTX, leflunomide, sulphasalazine, hydroxychloroquine and azathioprine) than that of the control arm who received DMARDs and placebo. The superior response was also seen in those who have been using 2 or more DMARDs. Rates of remission were higher in the tocilizumab arm (30%) than the control arm (3%). The efficacy of tocilizumab was also evaluated in those patients who had inadequate response to anti-tumor necrosis factor antagonists in the RADIATE 2 trial. Percentage of patients who achieved ACR20, ACR50 and ACR70 were 50%, 28.8% and 12.4% respectively in those who received tocilizumab 8 mg/kg and MTX. Only 10.1% of patients on placebo had ACR20 response by week 24. DAS28 remission rates were again better in the tocilizumab group. These 3 studies showed that tocilizumab in combination with DMARDs are efficacious for controlling RA activities in patients who have previously failed to respond adequately to conventional DMARDs and anti-TNF biologics.
While the above studies evaluating the clinical efficacy of tocilizumab in combination therapy, a Japanese trial, SATORI, 3 studied the effect of tocilizumab as monotherapy in active RA patients who had inadequate response to low dose MTX. Patients who received tocilizumab alone were able to achieve better ACR response. Percentages of patients with ACR20 response in the tocilizumab group and in the MTX group were 80.3% and 25.0% respectively.
AMBITION
4 study is in RA patients who have not previously failed MTX or biologic agents. 66% of 673 patients recruited were MTX naïve. By the end of week 24, nearly 70% of patients who received tocilizumab 8 mg/kg monotherapy achieved ACR20 response as compared to 44.1% in MTX monotherapy group. The tocilizumab group also showed better ACR50 and ACR70 response. Tocilizumab is the first biologics agent that has proven superiority over MTX in head to head study.
Radiological Outcome
Radiological outcome of tocilizumab were evaluated in two phase III trials. In the SAMURAI 5 study, 306 patients with active RA with a mean disease duration of 2.3 years and mean DAS28 of 6.5 were allocated to receive either tocilizumab monotherapy 8 mg/kg 4-weekly or conventional DMARDs for 52 weeks. Radiographs of hands and forefeet were scored by the van der Heijde modified Sharp method. By the end of the study, the tocilizumab group showed significantly less radiographic change in the total sharp score (TSS) than the DMARDs group. The mean change of TSS in the tocilizumab group was 2.3 as compared to 6.1 in the DMARDs group. The other trial, LITHE 7 study, has included nearly 2000 patients with moderate to severe RA with inadequate response to MTX. This is supposed to be a 2-year trial and is on-going. A greater proportion of patients treated with tocilizumab with MTX benefited from a significant inhibition of structural damage during the first year of therapy.
Long-term Efficacy
Long-term efficacy of tocilizumab monotherapy was evaluated in a 5-year extension trial (STREAM). 8 This is an open-label, long-term extension trial. One hundred and forty-three patients were enrolled with 94 patients completed the 5-year study. At the end of the study period, 79/94 (84%), 65/64 (69.1%) and 41/91 (43.6%) of the patients achieved ACR20, ACR50 and ACR70 response respectively. Over half of them achieved DAS28 remission. STREAM demonstrated the sustained long term efficacy of tocilizumab. Table 2 summarizes the ACR responses and DAS28 remission rates in the studies mentioned. 
Other Clinical Parameters
Besides the ACR improvement and the DAS28 remission, tocilizumab did improve other clinical parameters [1] [2] [3] [4] [5] [6] 8, 9 including swollen joint count, tender joint count and laboratory figures such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and haemoglobin (Hb) levels. Mean CRP levels had normalized at study end in patients treated with tocilizumab (8 mg/kg) monotherapy and in combination with DMARDs. 1,2,4-6 The improvement in clinical parameter was noticed as early as 2 weeks after institution of tocilizumab. Rise in Hb levels were also observed in these studies. This is because the production of hepcidin, a liver peptide that restricts iron availability, is inhibited by anti-IL6.
Health-related Quality of Life
Improvement in terms of HAQ, SF36 and FACIT-Fatigue scores were observed. [1] [2] [3] [4] [5] [6] 8, 9 Safety Profile Table 3 summaries the rates of adverse reactions in the phase III trials. Adverse events were common but most of them were mild, self-limiting infections or laboratory abnormalities. The most commonly reported adverse reactions were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased hepatic transaminases. 10 The rate of serious infections was 5.7 events per 100 patientyears as reported in the STREAM 8 trial. The most common infections were pneumonia, herpes zoster, acute bronchitis and pyelonephritis. So far, no increase incidence of tuberculosis was observed.
A total of 4 malignancies were identified in the STREAM 8 trial. These included bladder cancer, breast cancer, large intestine cancer and intraductal papilloma. The incidence was similar to that in the observational cohort of RA patients or the Japanese population data.
Commonly observed laboratory abnormalities were neutropenia, deranged liver function and deranged lipid profile.
Neutropenia was usually transient and of grade 1 or 2. In RADIATE 2 study, 28% of patients on tocilizumab 8 mg/kg plus MTX had transient neutropenia at some time during the study. Grade 3 or 4 neutropenia happened in 3.4% of patients No clear association between this adverse reaction and the occurrence of serious infections was observed.
The rise in hepatic transaminases was often less than three times of the upper normal limit and this was usually reversible upon withdrawal of tocilizumab. The increase of liver enzymes above five fold of upper normal limit that resulted in the termination of tocilizumab was less frequent. This occurred in 0.7% of patients receiving tocilizumab and DMARDs. 10 There was no fulminant hepatitis observed.
Rises in lipid parameters were not uncommon. Lipid-lowering agents were effective in combating the problem. The relationship with cardiovascular events was yet to be explored.
46 out of 2876 patients developed anti-tocilizumab antibodies according to the data from the European Medicine Agency. 10 Among them, six experienced medically significant hypersensitivity reaction.
Conclusion
This review demonstrated the clinical efficacy of tocilizumab and its safety profile. It is an important emerging treatment option for RA patients. Larger clinical trials are expected especially to study the long-term safety profile of tocilizumab.
